ClinConnect ClinConnect Logo
Search / Trial NCT01462435

Study of Diclofenac Capsules to Treat Pain Following Bunionectomy

Launched by IROKO PHARMACEUTICALS, LLC · Oct 27, 2011

Trial Information

Current as of May 02, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patient is male or female between 18 and 65 years of age
  • For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control
  • Has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures
  • Patient must be willing to stay at the study site ≥ 72 hours
  • Exclusion Criteria:
  • Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs
  • Patient has a current disease or history of a disease that will impact the study or the patient's well-being
  • Patient has used or intends to use any of the medications that are prohibited by the protocol
  • Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test
  • Patient has taken another investigational drug within 30 days prior to screening

About Iroko Pharmaceuticals, Llc

Iroko Pharmaceuticals, LLC is a biopharmaceutical company dedicated to advancing innovative pain management solutions through the development of novel therapeutic products. With a strong focus on utilizing proprietary technologies to enhance the safety and efficacy of non-opioid analgesics, Iroko aims to address the pressing challenges of pain relief while minimizing the risks associated with traditional pain medications. Committed to rigorous clinical research and a patient-centered approach, Iroko Pharmaceuticals strives to improve the quality of life for patients suffering from acute and chronic pain conditions.

Locations

Pasadena, Maryland, United States

Austin, Texas, United States

Phoenix, Arizona, United States

Salt Lake City, Utah, United States

Patients applied

0 patients applied

Trial Officials

Michael Golf, DPM

Principal Investigator

Premier Research Group Limited

Ira Gottlieb, DPM

Principal Investigator

Chesapeake Research Group, LLC

Kyle Patrick, DO

Principal Investigator

Premier Research Group Limited

S. Thomas Schiffgen, DPM

Principal Investigator

Premier Research Group Limited

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials